Financial Data and Key Metrics Changes - The net loss attributable to common stockholders for the year ended December 31, 2025, was approximately $45.9 million, compared to approximately $42.1 million for 2024, indicating an increase in losses [22] - Research and development expenses totaled approximately $20.7 million for the year ended December 31, 2025, down from approximately $33.2 million for 2024, due to lower expenses related to the Alzheimer's trial [23] - General and administrative expenses were approximately $10.3 million for the year ended December 31, 2025, compared to approximately $9.5 million for 2024 [23] - The company recorded a full impairment of its intangible asset of $16.5 million in 2025 following the release of phase II results of the Alzheimer's trial, which did not meet the clinical endpoint [23] - As of December 31, 2025, the company had cash and cash equivalents of approximately $24.8 million, sufficient to fund operations through Q1 2027 [24] Business Line Data and Key Metrics Changes - CORDStrom is the most advanced program and a major value driver for the company, with recent patient data showing clinically meaningful wound healing and improvements in quality of life for RDEB patients [5][6] - The XPro program for Alzheimer's disease is in a strong position, having completed the MINDFuL trial and aligned with the FDA on the development path, preparing for a phase III trial [7][8] Market Data and Key Metrics Changes - The company is preparing regulatory submissions for CORDStrom in both the U.K. and the U.S., with plans to file the MAA in the U.K. by the end of summer 2026 [5][15] - The company aims to submit the BLA to the FDA towards the end of 2026, with expectations of feedback or approvals in 2027 [25] Company Strategy and Development Direction - The company is focused on executing against important regulatory, clinical, and strategic milestones across its portfolio, particularly for CORDStrom and XPro [5][9] - CORDStrom is not just a single asset opportunity but a platform with broader potential for development in additional inflammatory and degenerative conditions [6] - The strategy includes advancing multiple differentiated platforms in parallel to create meaningful opportunities for value creation [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress of CORDStrom and its potential to address unmet medical needs for RDEB patients, emphasizing the urgency to bring the therapy to market [6][7] - The company remains committed to capital efficiency and maximizing shareholder value while minimizing unnecessary burn [21] - Management highlighted the importance of building partnerships and financial support to advance their programs [25] Other Important Information - The company completed its phase II trial in metastatic castration-resistant prostate cancer ahead of schedule and under budget, meeting its primary endpoint and two of its three secondary endpoints [8] - The company is actively seeking business partnerships to develop broader indications for CORDStrom beyond RDEB [15] Q&A Session Summary Question: Anticipated differences between an MAA and an FDA submission - Management indicated that the FDA requires U.K. donor materials to be screened for infectious disease markers in U.S. labs, necessitating the creation of new master seed stock for U.S. submission [33][34] Question: Interest from potential pharma partners for XPro - Management confirmed ongoing discussions with groups and emphasized the attractiveness of the XPro program for mid-sized and large pharma companies due to its potential in a large market [47][48]

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 was $7 million, a decrease of 13% from $8.1 million in Q4 2024 [11] - For the full year 2025, total revenue was $30.6 million compared to $34.6 million in 2024 [11] - Net income after tax for Q4 2025 was $1.6 million or $0.11 per diluted share, down from $2.2 million or $0.16 per diluted share in Q4 2024 [14] - Full year net income was $6.3 million or $0.45 per diluted share, compared to $3.7 million or $0.26 per diluted share in 2024 [15] - Adjusted EBITDA for Q4 2025 was $3.4 million, down from $3.8 million in Q4 2024 [16] Business Line Data and Key Metrics Changes - Franchise royalties for Q4 2025 were $6.6 million, down from $7.6 million in Q4 2024 [11] - For the full year 2025, franchise royalties were $29 million compared to $32.7 million in 2024 [12] - Service revenue in Q4 2025 was $392 thousand, compared to $428 thousand in Q4 2024 [12] Market Data and Key Metrics Changes - System-wide sales in Q4 2025 were $122.3 million, a decrease of 9.3% from $134.8 million in Q4 2024 [12] - For the full year, system-wide sales were $500.2 million, down 11.3% from $563.6 million in 2024 [12] - 68% of surveyed offices reported steady time to fill for open roles in 2025, indicating market stability [8] Company Strategy and Development Direction - The company announced a strategic decision to divest the permanent placement piece of MRI Network into a new entity, transitioning majority ownership to a leadership group of franchise owners [5] - HireQuest remains committed to MRI Network, retaining partial ownership and supporting the brand with essential infrastructure [6] - A share repurchase program was approved, allowing the company to repurchase up to $20 million of its outstanding shares [6] Management's Comments on Operating Environment and Future Outlook - The macro environment has created challenges for the staffing industry, but the company remains profitable and executed well in 2025 [4] - The company expects a stabilizing labor market in 2026, with trends such as AI, automation, and economic shifts shaping the hiring landscape [9] - Management believes the company is well-positioned to benefit from a stabilizing market and meet shifting employer demands [9] Other Important Information - The company ended 2025 with approximately $33 million in working capital, an increase from $25.1 million at the end of 2024 [17] - The company has paid a regular quarterly dividend since Q3 2020, with the most recent dividend being $0.06 per common share [17] Q&A Session Summary Question: Impact of stabilization on divisions - Management noted that stabilization in the market has not been more pronounced in any particular division but is evident across the board [22] Question: MRI transaction revenue and expense impact - The executive search portion of MRI contributed about $65 million in system-wide sales and just under $2 million for royalties in 2025, with minimal impact on profitability expected from the ownership change [25] Question: Update on acquisition pipeline - Management indicated a lack of recent acquisition activity, citing a dry spell in finding suitable deals, but remains open to opportunities [29]

Financial Data and Key Metrics Changes - For Q4 2025, revenue was approximately $24 million, a 19% increase year-over-year, while operating EBITDA exceeded $17 million, reflecting portfolio growth and cost improvements [4][10] - Full year revenue increased by 36% compared to 2024, with operating EBITDA for the year at $80.1 million, a 49% increase versus 2024 [4][5] - Adjusted cash flow from operations was $5.1 million in Q4 2025, compared to -$4.1 million in the prior year period, indicating improved operating performance [5][11] Business Line Data and Key Metrics Changes - The increase in revenue was primarily driven by the residential solar portfolio acquired from NJR and higher solar renewable energy credit revenues [10] - Core operating expenses, including SG&A and O&M, totaled $14.9 million in Q4 2025, down from $20.7 million in the same quarter of 2024 [11] Market Data and Key Metrics Changes - Total outstanding principal debt as of December 31, 2025, was $695.5 million, with a blended interest rate of approximately 6.1% [13] - Cash position at the end of 2025 was $93.1 million, compared to $98.8 million at the end of Q3 2025 [12] Company Strategy and Development Direction - The company’s strategy focuses on three key growth drivers: acquiring installed residential solar portfolios, expanding programmatic partnerships, and scaling Spruce Pro, a capital-light servicing platform [8][9] - The company aims to maximize optionality and enhance long-term financing efficiency through a comprehensive refinancing strategy [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company’s ability to execute a financing solution that strengthens the business and supports future growth [7] - The company exited 2025 with strong momentum, improved profitability, and a clear path to continued growth [9] Other Important Information - The company strategically extended its SP one facility to create additional flexibility for a broader refinancing opportunity [6][13] - The going concern disclosure is driven by accounting requirements and does not reflect the company’s operating performance [7] Q&A Session Summary Question: Revenue breakdown for SREC and services revenue - Management indicated that SREC revenue for the year was $21 million, and system lease or PPA revenue was $78 million [19][20] Question: Pipeline for Spruce Pro business growth - Management described a robust pipeline with both large and smaller opportunities, indicating active market engagement [21] Question: M&A pipeline and its relation to debt consolidation - Management confirmed an active M&A pipeline, stating that it operates independently from the SP one strategic extension [22]

Financial Data and Key Metrics Changes - For the full year 2025, RenovoRx generated over $1 million in revenue, with Q4 revenues at $238,000, reflecting strong initial adoption of RenovoCath [6][21] - Gross profit for Q4 was $210,000, resulting in a gross margin of 88% [22] - Research and development expenses for Q4 were $1.5 million, totaling $6.3 million for the year, indicating continued investment in clinical trials [22] - Selling, general, and administrative expenses for Q4 were $2.2 million, with a total of $7 million for the year, reflecting disciplined cost management [22] Business Line Data and Key Metrics Changes - The company exited Q4 with nine active commercial centers, with three becoming active in the last two weeks of the year [6][7] - As of February 27, 2026, 12 U.S. cancer centers are utilizing RenovoCath, with 21 additional centers evaluating the device, representing a tripling of the near-term pipeline compared to Q1 2025 [10] Market Data and Key Metrics Changes - The company is targeting approximately 36 active commercial sites by year-end 2026, tripling its current footprint of 12 [11][25] - The growth of active commercial site networks is expected to drive revenue growth, with a projected revenue range of $3 million to $4 million for 2026 [26] Company Strategy and Development Direction - The company is focused on scaling its commercial operations and expanding its active site network, supported by a robust pipeline of centers [11][12] - The transition of TIGeR-PaC trial sites to commercial use is seen as a critical step in driving revenue growth [9][52] - The company aims to leverage clinical data to build physician confidence and drive adoption of RenovoCath [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial potential of RenovoCath, citing strong physician demand and a validated commercial model [11][19] - The company anticipates Q1 2026 to be the strongest revenue quarter yet, with significant growth expected throughout the year [24][25] - Management emphasized the importance of disciplined growth and capital efficiency in scaling operations [13][22] Other Important Information - The company closed an oversubscribed private placement on March 23, 2026, resulting in gross proceeds of approximately $10 million, providing financial flexibility for growth initiatives [23][24] - The TIGeR-PaC trial is on track for completion by mid-2026, with positive data expected to be transformative for the business [18][19] Q&A Session Summary Question: Transitioning TIGeR-PaC centers to commercial customers - Management indicated that transitioning existing trial centers to commercial use is simpler due to established familiarity and training, with most centers already having pricing agreements in place [29][30] Question: Catheter outlook and revenue expectations - Management refrained from providing specific revenue guidance but indicated strong confidence in Q1 performance based on early 2026 activity [34][36] Question: Active centers and revenue growth drivers - Management clarified that growth is driven by both new centers and increased usage at existing centers, with a focus on expanding the active site network [36][38] Question: Sales and marketing personnel adequacy - Management confirmed that the current sales team is sufficient to reach the target of 36 active centers, with plans to add more personnel as needed [63]

Financial Data and Key Metrics Changes - Sangamo reported significant pipeline progress in 2025, including a positive top-line result from the STAR study in Fabry disease, with a positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks across all dosed patients [5] - The company raised over $130 million in funding since the start of 2025 through non-dilutive license fees, milestone payments, and equity financing [6] Business Line Data and Key Metrics Changes - The STAR study for ST-920, an investigational gene therapy for Fabry disease, is in the rolling submission phase for a Biologics License Application (BLA) to the FDA, with both non-clinical and clinical modules submitted [9] - The company transitioned to a clinical-stage neurology company with six clinical sites activated in the phase I/II STAND study for chronic neuropathic pain [5] Market Data and Key Metrics Changes - The company received Fast Track designation from the FDA for ST-503, an investigational epigenetic regulator for patients with intractable pain due to small fiber neuropathy (SFN) [12] - The STAR study data showed improved kidney function and stabilization in cardiac function, which is critical given the cardiovascular risks associated with Fabry disease [11] Company Strategy and Development Direction - Sangamo's primary focus is securing a commercial partner for Fabry disease, with ongoing discussions with multiple potential partners [17] - The company aims to manage its cash runway carefully while advancing its pipeline and fulfilling regulatory requirements for its therapies [16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by regulatory and market uncertainties but expressed optimism about the progress made in the pipeline and the potential for ST-920 to transform Fabry disease treatment [5][16] - The company is committed to prudent financial management while seeking additional capital and strategic options for its assets [17] Other Important Information - The company has made significant advancements in its neurology pipeline, including the activation of additional clinical sites for ST-503 and the completion of preclinical studies for ST-506 [14] - Sangamo's collaborations with prominent companies in the neurology space highlight its position as a collaborator of choice for neurotropic capsids [16] Q&A Session Summary Question: Can you provide more color on the revised timing for the Fabry BLA submission? - Management indicated that CMC activities are critical for the filing and that they are following FDA guidance closely to ensure a successful submission [20][21] Question: What is the status of the Fabry partnership discussions? - Management confirmed ongoing discussions with multiple new partners and emphasized the complexity of the due diligence process [22] Question: Have there been any additional interactions with the FDA regarding the eGFR slope as a primary endpoint? - Management stated that the last interaction with the FDA was in October, where they reiterated that the eGFR could be used for accelerated approval [27][28] Question: Regarding prion disease and the STAC-BBB capsid, what is the timeline for clinical proof of concept? - Management clarified that the choice of AAV9 for neuropathic pain was based on prior knowledge and that they are pleased with the enthusiasm from partners regarding the STAC-BBB capsid [33][34]

Financial Data and Key Metrics Changes - Net premiums earned for Q4 2025 decreased to $555,000 from $595,000 in Q4 2024, attributed to lower average rates on reinsurance contracts [6][10] - Total revenue for Q4 2025 increased to $576,000 from $422,000 in the prior year [8][11] - Net income for Q4 2025 was $120,000 or $0.02 per share, compared to a net loss of $460,000 or $0.05 per share in Q4 2024 [13] - For the fiscal year 2025, total revenues were $2.58 million, up from $546,000 in 2024 [11][14] - Total expenses for Q4 2025 rose to $1.04 million from $497,000 in Q4 2024, primarily due to underwriting losses from Hurricane Milton [12][18] Business Line Data and Key Metrics Changes - The loss ratio for Q4 2025 increased to 80.9%, and for the fiscal year 2025, it rose to 119.9%, due to losses from Hurricane Milton [16][18] - The acquisition cost ratio remained stable at 11% for both the quarter and year ended December 31, 2025 [17] - The expense ratio for Q4 2025 increased to 106.7% from 83.5% in Q4 2024, and for the fiscal year, it increased to 144.2% from 94.3% [17][18] Market Data and Key Metrics Changes - The investment portfolio decreased to $0 at December 31, 2025, from $115,000 the previous year, due to the sale of equity securities [19] - Cash and cash equivalents increased by $1.08 million to approximately $7 million from $5.89 million as of December 31, 2024 [19] Company Strategy and Development Direction - The company focuses on disciplined reinsurance business with a strategy centered on low frequency, high severity risk, emphasizing data-driven underwriting [4][5] - SurancePlus aims to expand reinsurance on-chain, broadening access to an asset class traditionally limited to institutional partnerships [5] - The company is exploring opportunities to extend its model into high-quality, cash-generating assets, including the tokenization of data center revenue streams [21] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the 2026/2027 contract cycle, targeting returns of 20% and 42% for their offerings [21] - Industry reports suggest favorable conditions due to El Niño, presenting potential opportunities [21] - The company believes its current market valuation does not fully reflect its balance sheet strength and ongoing opportunities to enhance shareholder value [21] Other Important Information - The company has made significant progress in expanding its platform through strategic relationships, including entry into the Solana ecosystem [21] - The Balanced-Yield Token is tracking 25% ahead of its 20% target, while the High-Yield Token is tracking its 42% target [21] Q&A Session Summary Question: Can you expand on the tokenization of artificial intelligence infrastructure? - Management indicated that they are evaluating strategic relationships for data center revenue streams, which could significantly enhance shareholder value [24][25] Question: Is the company in a good position regarding cash balances? - Management confirmed having approximately $6.9 million in cash and restricted cash, positioning the company well for future opportunities [27]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported a net loss of approximately $4.1 million, or $0.36 per share, compared to a net loss of approximately $5.9 million, or $0.54 per share, in Q4 2024, reflecting improved financial performance [31] - Full-year 2025 R&D expenses were approximately $11.5 million, down from approximately $16.1 million in 2024, primarily due to a reduction in research studies and materials [32] - The net loss for the full year 2025 was approximately $17.1 million, or $1.57 per share, compared to approximately $20.8 million, or $1.93 per share, for 2024, indicating a decrease in losses [33] Business Line Data and Key Metrics Changes - The company achieved clinical validation across multiple programs, including LP-300 and LP-184, with significant milestones in their clinical trials [3][4] - The LP-300 program is focused on a significant unmet need in lung cancer, particularly among never smokers, with a market opportunity estimated at over $4 billion annually [6] - The LP-184 phase I trial showed a 48% clinical benefit rate in heavily pretreated advanced cancer patients, validating the synthetic lethality hypothesis [9] Market Data and Key Metrics Changes - The estimated annual market potential for the company's AI-driven clinical pipeline exceeds $15 billion and approaches $20 billion [4] - The company is actively exploring global collaboration opportunities to maximize LP-300's commercial potential [9] Company Strategy and Development Direction - The company is positioning to advance clinical programs and expand the RADR platform's commercial reach globally through a new AI Center of Excellence in India [4] - The strategy includes leveraging AI and machine learning to transform drug development processes, aiming to reduce costs and timelines significantly [2][38] - The company plans to launch the withZeta platform, which integrates advanced AI capabilities for drug discovery, at the upcoming AACR conference [37] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of AI technologies in the future of medicine and drug development, predicting significant returns for investors and patients [2] - The company is focused on executing a dual engine strategy, advancing clinical assets while scaling the AI platform for commercial deployment [39] - Management expressed confidence in the potential for AI to accelerate drug development timelines and improve patient outcomes [38] Other Important Information - The company has received FDA Orphan Drug Designation for multiple programs, which could provide pathways for FDA Priority Review Vouchers upon potential approval [15][20] - The company reported a cash position of approximately $10.1 million as of December 31, 2025, and indicated the need for substantial additional funding in the near future [34] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Financial Data and Key Metrics Changes - For Q4 2025, the company reported a net loss of $35.7 million, an increase from a $24.7 million loss in Q4 2024, primarily due to a $6.8 million increase in impairment expense and a $3.4 million increase in foreign exchange loss [13][14][16] - The full year 2025 net loss was $48.4 million, compared to a shorter six-month fiscal stub period in 2024 [18][19] - The company ended the quarter with cash and working capital positions of $152.3 million and $147.6 million, respectively, compared to $31.2 million and $27.5 million in the prior year [19][20] Business Line Data and Key Metrics Changes - The SWA project is expected to have a production capacity of 22,500 tons per year of battery-quality lithium carbonate in its initial phase, with plans to reach over 100,000 tons per year through multiple projects [3][4] - The company signed its first binding commercial offtake agreement with Trafigura for 8,000 metric tons per year, representing over 40% of the targeted offtake for the initial phase of the SWA project [5][10] Market Data and Key Metrics Changes - The company received indications of interest for over $1 billion in project financing for the SWA project from major export credit agencies and commercial banks, exceeding the targeted debt amount [5][21] - The lithium pricing environment has improved, leading to increased interest from counterparties for offtake agreements [26][27] Company Strategy and Development Direction - The company aims to secure over 80% of its production under long-term offtake contracts before the final investment decision (FID) [10][28] - The focus is on advancing the SWA project and the Franklin project in East Texas, with plans to release a preliminary feasibility study for the Franklin project within the next 12 months [12][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to reach a satisfactory outcome in customer offtake negotiations, which are critical for project financing [11][39] - The company is well-positioned with a portfolio of high-quality and scalable assets, aiming for a final investment decision at SWA before moving to construction in 2026 [23][40] Other Important Information - The company is pursuing an engineering, procurement, construction, and commissioning (EPCC) model for the downstream portion of the project and an engineering, procurement, and construction management (EPCM) model for the upstream portion [8][9] - The project is undergoing an environmental assessment under the National Environmental Policy Act (NEPA), expected to be completed in the second quarter [9][10] Q&A Session Summary Question: Changes in offtake discussions over the last 6-12 months - Management noted that the market has evolved positively, with more counterparties interested in discussions due to improved lithium pricing [26][27] Question: Expectation of another offtake agreement before financing concludes - Management confirmed the plan to have over 80% of volumes contracted prior to FID, with announcements expected in the coming quarter [28] Question: Clauses or caveats that project debt lenders are looking for in offtake contracts - The 80% target is an internal standard, with lenders looking for take-or-pay contracts with credit-worthy counterparties [31][32] Question: Construction period and CapEx timeline - The company is guiding towards commercial production in 2029, with a focus on aligning construction and commissioning schedules with offtake contracts [34] Question: Gating items to FID - Management indicated that offtake agreements are the hardest to predict in terms of timing, while other items are progressing well [38][39] Question: Inflationary pressures for CapEx items - Management stated that vendor pricing is stable, with allowances made for price growth and inflationary effects in final contract amounts [71][73]

Financial Data and Key Metrics Changes - Consolidated revenue increased to $118 million, up 18% from $100 million in 2024, driven by higher silver production and strong realized prices [17] - Consolidated attributable silver production reached 2.65 million oz, with approximately 3.4 million oz of silver equivalent, including byproducts [17] - Net loss reported at $87 million or $0.33 per share in 2025, compared to a net loss of $49 million or $0.46 per share in 2024 [18] Business Line Data and Key Metrics Changes - Significant increase in silver production by 52% to 2.65 million oz, with record production of 1.2 million oz at Cosalá [4][5] - Galena achieved consistent productivity gains alongside major capital projects and integration of the Crescent Mine [5][10] - Transition to long hole stoping at Galena has shown a 200% improvement in mucking operations, moving around 200 tons of ore per shift [8][9] Market Data and Key Metrics Changes - Institutional ownership increased from 7% in late 2024 to over 65%, indicating strong market support [20] - Americas Gold and Silver added to the VanEck GDXJ and SIL ETFs, with increased analyst coverage [20] Company Strategy and Development Direction - Focus on strengthening U.S. critical minerals supply chains and expanding silver and antimony production [12][13] - Introduction of a formal 2026 production cost and capital guidance, expecting silver production of 3.2 million-3.6 million oz at an AISC of $30-$35 per ounce sold [13][15] - Major investments planned for infrastructure upgrades and operational improvements at Galena and Crescent [15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future silver production growth as the Crescent Mine restarts and EC120 operations optimize [19] - The company is excited about the potential of new high-grade discoveries and the ongoing exploration program [11][21] - Management highlighted the importance of safety, achieving over 550,000 man-hours without lost time accidents [3] Other Important Information - The company launched its largest exploration program in history, with approximately 64,000 m of drilling planned across the Galena Complex [11] - A joint venture with United States Antimony was announced to build and operate a new antimony facility at the Galena Complex [12] Q&A Session Summary Question: Production guidance breakdown for Cosalá and Galena - Management provided a range of 2.2 million-2.6 million oz from Galena and 1.2 million-1.4 million oz from Mexico for 2026 [27][28] Question: Capital allocation split for the year - Total capital expenditures targeted between $90 million and $120 million, with $60 million-$80 million for growth and $30 million-$40 million for sustaining [33] Question: Update on Relief Canyon and antimony JV - An internal study on Relief Canyon is planned, while the antimony JV is progressing faster than expected [35][38] Question: 2026 guidance and production trajectory - Crescent will contribute a small amount to production in 2026, with a focus on extending vein systems [41][42] Question: New discoveries and their impact - The new 520 vein is under exploration, with potential for significant discoveries in the district [75]

Financial Data and Key Metrics Changes - Consolidated revenue increased to $118 million, up 18% from $100 million in 2024, driven by higher silver production and strong realized prices [17] - Consolidated attributable silver production reached 2.65 million ounces, with approximately 3.4 million ounces of silver equivalent, including byproducts [17] - Net loss reported at $87 million or $0.33 per share in 2025, compared to a net loss of $49 million or $0.46 per share in 2024 [18] Business Line Data and Key Metrics Changes - Significant increase in attributable silver production by 52% to 2.65 million ounces, with a record production year of 1.2 million ounces at Cosalá [4][17] - Galena achieved consistent productivity gains alongside major capital projects and integration of the newly acquired Crescent Mine [5][10] Market Data and Key Metrics Changes - Institutional ownership increased from 7% in late 2024 to over 65%, indicating strong market support [20] - Americas Gold and Silver added to the VanEck GDXJ and SIL ETFs, enhancing visibility and investor interest [20] Company Strategy and Development Direction - Focus on strengthening U.S. critical minerals supply chains and advancing operational improvements at Galena and Crescent [13][15] - Introduction of a formal 2026 production cost and capital guidance, expecting consolidated silver production of 3.2-3.6 million ounces [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future silver production growth as the company advances the restart of the Crescent Mine and optimizes the EC-120 mine at Cosalá [19] - The company is excited about the potential in antimony production and the ongoing exploration initiatives [12][19] Other Important Information - Major investments made into underground mining fleet and infrastructure upgrades, including the installation of modern fiber optic communication systems [9][91] - The company launched the largest exploration program in its history, planning approximately 64,000 meters of drilling across the Galena Complex [11] Q&A Session Summary Question: Production guidance breakdown for Cosalá and Galena - Management provided a range of 2.2-2.6 million ounces from Galena and 1.2-1.4 million ounces from Mexico for 2026 [27][28] Question: Capital allocation split for the year - Total capital expenditures targeted between $90 million and $120 million, with a significant portion allocated to Crescent [35] Question: Update on Relief Canyon and antimony JV - An internal study on Relief Canyon is planned, while the antimony JV is progressing faster than expected [37][40] Question: 2026 guidance and production trajectory - Crescent will contribute a small amount to production in 2026, with a focus on extending vein systems [43][44] Question: Discovery potential at El Alacrán - El Alacrán is a new discovery that could potentially feed into the milling center in the future [51][52] Question: Long hole stoping performance at Galena - Long hole stoping has been successfully implemented, with management focusing on optimizing drilling and blasting patterns [70][71]